Key result
High LGE localisation score is linked to ~20.5-fold higher major cardiovascular events risk in cardiac sarcoidosis.
Why the study?
Does the quantification of left ventricular fibrosis mass and its anatomical localisation by LGE-CMR improve risk stratification for major adverse cardiac events and ventricular tachyarrhythmias in patients with cardiac sarcoidosis?
Cohort (n=81)
Both independent observers were blinded to the patients' identities and clinical profiles
Yes
Does the quantification of left ventricular fibrosis mass and its anatomical localisation by LGE-CMR improve risk stratification for major adverse cardiac events and ventricular tachyarrhythmias in patients with cardiac sarcoidosis?
Combining left ventricular fibrosis mass quantification with anatomical localisation of LGE to the basal anterior/anteroseptal LV and RV on cardiac MRI significantly improves risk stratification for MACE and ventricular tachyarrhythmias in patients with cardiac sarcoidosis.
Answers are grounded in this paper and cite their sources.
May support refined risk stratification in cardiac sarcoidosis; hypothesis-generating and requires prospective validation.
BACKGROUND: The presence of myocardial fibrosis by cardiac MRI has prognostic value in cardiac sarcoidosis, and localisation may be equally relevant to clinical outcomes. OBJECTIVE: We aimed to analyse cardiac damage and function in detail and explore the relationship with clinical outcomes in patients with cardiac sarcoidosis using cardiac MRI. METHODS: We included 81 consecutive patients with cardiac sarcoidosis undergoing cardiac MR. Left ventricular mass and fibrosis mass were calculated, and localisation was analysed using a 17-segment model. Participants underwent follow-up through 2015, and the development of major adverse cardiac events including ventricular tachyarrhythmias was recorded. RESULTS: Increased left ventricular fibrosis mass was associated with increased prevalence of ventricular tachyarrhythmias (p<0.001). When localisation was defined as the sum of late gadolinium enhancement in the left ventricular basal anterior and basal anteroseptal areas, or the right ventricular area, it was associated with ventricular tachyarrhythmias (p<0.001). Kaplan-Meier analysis during a median follow-up of 22.1 months showed that both the mass and localisation groupings for fibrosis were significantly associated with major adverse cardiac events or ventricular tachyarrhythmias and that when combined, the risk stratification was better than for each variable alone (p<0.001, respectively). By Cox-proportional hazard risk analysis, the localisation grouping was an independent predictor for the both. CONCLUSIONS: In patients with cardiac sarcoidosis, both fibrosis mass and its localisation to the basal anterior/anteroseptal left ventricle, or right ventricle was associated with the development of major adverse cardiac events or ventricular tachyarrhythmias. Cardiac MR with late gadolinium enhancement may be useful for improving risk stratification in patients with cardiac sarcoidosis.
No takes yet. Share an insight, caveat, or question.
Yasuda et al. (2016) conducted a cohort in Cardiac sarcoidosis (definite or suspected) (n=81). High LGE localisation score (LS ≥2: summation of late gadolinium enhancement in the basal anterior LV, basal anteroseptal LV, and RV) and LV fibrosis mass index (≥5.12 g/m2) vs. Low LGE localisation score (LS ≤1) and LV fibrosis mass index (<5.12 g/m2) was evaluated on Major adverse cardiac events (MACE: combination of cardiac mortality, admission for worsening HF, advanced AVB, and ventricular tachyarrhythmias) (HR 20.487, 95% CI 3.504 to 398.919, p=<0.001). High LGE localisation score (≥2 in basal anterior/anteroseptal LV or RV) independently predicted major cardiovascular events and VA in cardiac sarcoidosis.
Synapse has enriched 10 related papers. Consider them for comparative context: